Trials / Terminated
TerminatedNCT01482013
Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- High Point Pharmaceuticals, LLC. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and tolerability study investigating the effect of HPP854 in subjects with mild cognitive impairment or a diagnosis of mild Alzheimer's disease. The study will assess the pharmacokinetic and pharmacodynamic relationships of HPP854 in plasma, pharmacodynamic relationship in cerebral spinal fluid and plasma concentration profiles for Amyloid-Beta.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HPP854 | Oral, once a day for 28 days. |
| DRUG | Placebo | Oral, once a day for 28 days. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2011-11-30
- Last updated
- 2012-08-30
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01482013. Inclusion in this directory is not an endorsement.